The rhetorical—if not yet real—decoupling between America and China, which business is afraid to speak out against, however ...

Pfizer's attractive dividend yield and low P/E ratio make it appealing. Learn why PFE stock's valuation risks may be higher ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.

How GLP-1 drugs, regulatory concerns, and more factors are shaping the sector. Plus, 3 undervalued healthcare stocks.

Alnylam Pharmaceuticals' shares rose about 7% before the bell on Friday following U.S. approval for its drug for a rare and deadly heart disease, securing an entry into a market dominated by Pfizer's ...

(Reuters) -U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, ...

If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (NYSE: PFE). The ...

The disposal represents Pfizer's exit from its investment in Haleon, which originated from a JV formed with GSK in 2019.

Pfizer stock has delivered its long-term shareholders a dividend that has grown for 16 consecutive years. The pace of those ...